PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 139 filers reported holding PROTAGONIST THERAPEUTICS INC in Q2 2021. The put-call ratio across all filers is 2.23 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,004,703 | +22.4% | 60,234 | +102.6% | 0.00% | +50.0% |
| Q2 2023 | $821,060 | +20.4% | 29,727 | +0.2% | 0.00% | 0.0% |
| Q1 2023 | $682,019 | +33.6% | 29,653 | -36.6% | 0.00% | +100.0% |
| Q4 2022 | $510,675 | +50967.5% | 46,808 | +167071.4% | 0.00% | – |
| Q2 2022 | $1,000 | -100.0% | 28 | -100.0% | 0.00% | -100.0% |
| Q3 2021 | $2,326,000 | -16.4% | 131,282 | +111.7% | 0.00% | -20.0% |
| Q2 2021 | $2,783,000 | +221.0% | 62,015 | +44.2% | 0.01% | +150.0% |
| Q4 2020 | $867,000 | +43250.0% | 42,992 | +40844.8% | 0.00% | – |
| Q3 2020 | $2,000 | -50.0% | 105 | -65.5% | 0.00% | – |
| Q2 2019 | $4,000 | +100.0% | 304 | +74.7% | 0.00% | – |
| Q1 2019 | $2,000 | -97.6% | 174 | -98.6% | 0.00% | – |
| Q2 2018 | $85,000 | -84.5% | 12,682 | -80.2% | 0.00% | -100.0% |
| Q1 2018 | $549,000 | +51.7% | 63,921 | +266.8% | 0.00% | +100.0% |
| Q4 2017 | $362,000 | – | 17,425 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 2,449,183 | $19,373,000 | 4.95% |
| Bain Capital Life Sciences Investors, LLC | 2,260,572 | $17,881,000 | 2.10% |
| Finepoint Capital LP | 735,126 | $5,815,000 | 2.01% |
| Altium Capital Management LP | 365,100 | $2,888,000 | 1.16% |
| RTW INVESTMENTS, LP | 4,794,499 | $37,924,000 | 0.98% |
| Amitell Capital Pte Ltd | 50,129 | $397,000 | 0.90% |
| COWEN AND COMPANY, LLC | 1,065,724 | $8,430,000 | 0.81% |
| Tri Locum Partners LP | 155,000 | $1,226,000 | 0.50% |
| BVF INC/IL | 1,106,838 | $8,755,000 | 0.42% |
| HighVista Strategies LLC | 46,459 | $367,000 | 0.22% |